Business
BELLUS Health Provides Update on Project Pipeline and Reports Financial and Operating Results for the Second Quarter Ended June 30, 2016
BELLUS Health Provides Update on Project Pipeline and Reports Financial and Operating Resu...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nBELLUS Health Provides Update on Project Pipeline and Reports Financial and Operating Results for the Second Quarter Ended June 30, 2016\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen4{\nBORDER-BOTTOM:black 1pt solid; TEXT-ALIGN: LEFT; BORDER-LEFT:black 1pt solid; PADDING-LEFT:0.50em; PADDING-RIGHT:0.50em; VERTICAL-ALIGN: BOTTOM; BORDER-TOP:black 1pt solid; BORDER-RIGHT:black 1pt solid\n}\n.prngen1{\nBORDER-BOTTOM:black 1pt solid; BORDER-LEFT:black 1pt solid; BORDER-TOP:black 1pt solid; BORDER-RIGHT:black 1pt solid\n}\n.prngen3{\nBORDER-BOTTOM:black 1pt solid; TEXT-ALIGN: CENTER; BORDER-LEFT:black 1pt solid; PADDING-LEFT:0.50em; PADDING-RIGHT:0.50em; VERTICAL-ALIGN: BOTTOM; BORDER-TOP:black 1pt solid; BORDER-RIGHT:black 1pt solid\n}\n.prngen5{\nBORDER-BOTTOM:black 1pt solid; TEXT-ALIGN: CENTER; BORDER-LEFT:black 1pt solid; PADDING-LEFT:0.50em; PADDING-RIGHT:0.67em; VERTICAL-ALIGN: BOTTOM; BORDER-TOP:black 1pt solid; BORDER-RIGHT:black 1pt solid\n}\n.prngen2{\nBORDER-BOTTOM:black 1pt solid; TEXT-ALIGN: RIGHT; BORDER-LEFT:black 1pt solid; PADDING-LEFT:0.50em; PADDING-RIGHT:0.67em; VERTICAL-ALIGN: BOTTOM; BORDER-TOP:black 1pt solid; BORDER-RIGHT:black 1pt solid\n}\n\n\n\n\n\n\nBELLUS Health Provides Update on Project Pipeline and Reports Financial and Operating Results for the Second Quarter Ended June 30, 2016\nCanada NewsWire\nLAVAL, QC, Aug. 9, 2016\n\n\n\nLAVAL, QC, Aug. 9, 2016 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a drug development company focused on rare diseases, today reported its financial and operating results for the second quarter ended June 30, 2016. All currency figures reported in this press release are in Canadian dollars, unless otherwise specified.\n\nHighlights \n\n\nAnnounced top-line results from the KIACTA™ Phase 3 Confirmatory Study for the treatment of AA amyloidosis; KIACTA™ did not meet the primary efficacy endpoint in slowing renal function decline and continues to be evaluated in order to determine next steps for the program; \nSubsequent to quarter end, completed an additional Shigamab&#x...